Skip to main content
Citius Pharmaceuticals, Inc. logo

Citius Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · CTXR ISIN · US17322U2078 LEI · 5493005C10W36P4KQP40 US Manufacturing
Open in API
Filings indexed 623 across all filing types
Latest filing 2016-06-13 Merger & Acquisition
Country US United States of America
Listing US CTXR

About Citius Pharmaceuticals, Inc.

https://www.citiuspharma.com/

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company that develops and commercializes critical care products. The company's diversified pipeline focuses on anti-infectives in adjunct cancer care, stem cell therapies, and prescription products. Its portfolio includes LYMPHIR™, an FDA-approved therapy for adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Key product candidates in development include Mino-Lok®, an antibiotic lock solution intended to treat patients with catheter-related bloodstream infections, and Halo-Lido, a topical formulation for the treatment of hemorrhoids. Additionally, the company is advancing a stem cell therapy platform for conditions such as acute respiratory distress syndrome (ARDS).

Recent filings

Filing Released Lang Actions
FORM 8-K/A
Merger & Acquisition Classification · 95% confidence The document is a Form 8-K/A, which is an amendment to a previously filed Form 8-K. It provides updated financial statements and pro forma financial information related to a merger/acquisition transaction. The document includes financial statements of the acquired business and unaudited pro forma consolidated financial statements. The presence of merger-related financial disclosures and the amendment nature of the filing indicate this is related to merger and acquisition activity. The document is not a full annual or quarterly report, nor is it a simple announcement or certification. Therefore, the most appropriate classification is 'Merger & Acquisition' (MA). The document length is under 5,000 characters but contains substantive financial data and exhibits, so it is not merely an announcement. Confidence is high due to clear references to merger agreements and financial statements related to the acquisition.
2016-06-13 English
FORM 10-Q
Interim / Quarterly Report Q2 2016
2016-05-20 English
NT 10-Q
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25 filed with the SEC, which is a Notification of Late Filing for a Form 10-Q quarterly report for the period ended March 31, 2016. It explains the reasons for the delay in filing the Form 10-Q and does not contain the actual financial statements or substantive financial data. The document is relatively short (3828 characters) and serves as an announcement of a late filing rather than the report itself. According to the rules, such a notification should be classified as a Regulatory Filing (RNS) because it is a compliance document related to the filing process and not the financial report itself.
2016-05-17 English
FORM 3
Director's Dealing
2016-04-19 English
FORM 3
Director's Dealing
2016-04-15 English
FORM 4
Director's Dealing
2016-04-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.